The Arizona Clinical Oncology Society

Yousef Zakharia, MD, discussed some of the available combination therapies for non–clear cell renal cell carcinoma treatment.

During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.

During a Targeted Oncology™ Community Case Forum™ event in partnership with The Arizona Clinical Oncology Society, Sujith R. Kalmadi, MD, reviewed data from the most important recent phase 3 trials of chemoimmunotherapy in advanced non–small cell lung cancer.

In a comprehensive review of the last 20 years of advancements and challenges in the pancreatic adenocarcinoma landscape, Dr. Tomsilav Dragovich highlights how treatment has evolved for this patient population.

The landscape for patients with pancreatic ductal adenocarcinoma has shifted due to novel targeted therapies that are opening new options for patients.

Lynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.